adding glp-1 to insulin A new ACP Journal Club is online now. Read about tailored precision immunotherapy for #sepsis, RAs for adults with #T1D and overweight or obesity, and more new evidence for #InternalMedicine from GLP-1 for Weight Loss and

Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts

Apc fl/fl

By paying attention to how you feel during and after you eat, you can adjust your habits to help ease these feelings of discomfort

Liraglutide also lowered SBP in individuals with T1DM (Class IV

Current 2026 approved GLP-1 RA medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)

Experts agree that nonmedical conditions such as availability, reimbursement policies, and costs may limit GLP1-RAs/SGLT2is combined therapy